CLEVELAND--(BUSINESS WIRE)--Centerline Biomedical, Inc. (âCenterlineâ), an innovative leader in cardiovascular navigation and visualization systems, announced the appointment of Jim Dillon as President and Chief Executive Officer (CEO) and a member of its board of directors. He will assume his responsibilities on August 18, 2025. Mr. Dillon succeeds Gulam Khan, who has served as CEO since October 2022. Mr. Khan led Centerline Biomedical through a period of portfolio development. During his tenu
Related Questions
How will Jim Dillonâs leadership and strategic vision affect Centerline Biomedicalâs growth prospects and market positioning?
What immediate impact might the CEO transition have on CLBNâs stock volatility and trading volume?
Are there any planned operational or product development changes under the new CEO that could influence revenue forecasts?